T
Tomohiro Ozaki
Researcher at Kindai University
Publications - 22
Citations - 543
Tomohiro Ozaki is an academic researcher from Kindai University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 8, co-authored 14 publications receiving 287 citations.
Papers
More filters
Journal ArticleDOI
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kazuhiko Nakagawa,Edward B Garon,Takashi Seto,Makoto Nishio,Santiago Ponce Aix,Luis Paz-Ares,Chao-Hua Chiu,Keunchil Park,Silvia Novello,Ernest Nadal,Fumio Imamura,Kiyotaka Yoh,Jin-Yuan Shih,Kwok Hung Au,Denis Moro-Sibilot,Sotaro Enatsu,Annamaria Zimmermann,Bente Frimodt-Moller,Carla Visseren-Grul,Martin Reck,Quincy Chu,Alexis B. Cortot,Jean-Louis Pujol,Elizabeth Fabre,Corinne Lamour,Helge Bischoff,Jens Kollmeier,M Kimmich,Walburga Engel-Riedel,Stefan Hammerschmidt,Wolfgang Schütte,Konstantinos N. Syrigos,James Chung-Man Ho,Kwok-Hung Au,Andrea Ardizzoni,Giulia Pasello,Vanessa Gregorc,Alessandro Del Conte,Domenico Galetta,Toshiaki Takahashi,Toru Kumagai,Katsuyuki Hotta,Yasushi Goto,Yukio Hosomi,Hiroshi Sakai,Yuichi Takiguchi,Young Hak Kim,Takayasu Kurata,Hiroyuki Yamaguchi,Haruko Daga,Isamu Okamoto,Miyako Satouchi,Satoshi Ikeda,Kazuo Kasahara,Shinji Atagi,Koichi Azuma,Keisuke Aoe,Yoshitsugu Horio,Nobuyuki Yamamoto,Hiroshi Tanaka,Satoshi Watanabe,Naoyuki Nogami,Tomohiro Ozaki,Ryo Koyama,Tomonori Hirashima,Hiroyasu Kaneda,Keisuke Tomii,Yuka Fujita,Masahiro Seike,Naoki Nishimura,Terufumi Kato,Masao Ichiki,Hideo Saka,Katsuya Hirano,Yasuharu Nakahara,Shunichi Sugawara,Sang-We Kim,Young Joo Min,Hyun Woo Lee,Jin-Hyoung Kang,Ho Jung An,Ki Hyeong Lee,Jin Soo Kim,Gyeong-Won Lee,Sung Yong Lee,A. Alexandru,Anghel Adrian Udrea,Óscar Juan-Vidal,Ernest Nadal-Alforja,Ignacio Gil-Bazo,Santiago Ponce-Aix,Belén Rubio-Viqueira,Miriam Alonso Garcia,Enriqueta Felip Font,Jose Fuentes Pradera,Juan Coves Sarto,Meng-Chih Lin,Wu Chou Su,Te Chun Hsia,Gee-Chen Chang,Yu-Feng Wei,Jian Su,Irfan Cicin,Tuncay Göksel,Hakan Harputluoglu,Ozgur Ozyilkan,Ivo Henning,Sanjay Popat,Olivia Hatcher,Kathryn Mileham,Jared Acoba,Edward B. Garon,Gabriel Jung,Moses Sundar Raj,William J. Martin,Shaker R. Dakhil +115 more
TL;DR: The RELAY trial as mentioned in this paper evaluated erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC.
Journal ArticleDOI
Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Isamu Okamoto,Hiroshi Nokihara,Shogo Nomura,Seiji Niho,Shunichi Sugawara,Hidehito Horinouchi,Koichi Azuma,Yasuto Yoneshima,Haruyasu Murakami,Yukio Hosomi,Shinji Atagi,Tomohiro Ozaki,Atsushi Horiike,Yuka Fujita,Hiroaki Okamoto,Masahiko Ando,Nobuyuki Yamamoto,Yuichiro Ohe,Kazuhiko Nakagawa +18 more
TL;DR: Carboplatin-pemetrexed treatment followed by pemetrexe maintenance is a valid option for first-line treatment of elderly patients with advanced nonsquamous NSCLC.
Journal ArticleDOI
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)
Ryoji Kato,Hidetoshi Hayashi,Yasutaka Chiba,Eriko Miyawaki,Junichi Shimizu,Tomohiro Ozaki,Daichi Fujimoto,Ryo Toyozawa,Atsushi Nakamura,Toshiyuki Kozuki,Kentaro Tanaka,Shunsuke Teraoka,Kazuhiro Usui,Kazumi Nishino,Osamu Hataji,Keiichi Ota,Noriyuki Ebi,Sho Saeki,Yuki Akazawa,Motoyasu Okuno,Nobuyuki Yamamoto,Kazuhiko Nakagawa +21 more
TL;DR: CAP showed a significantly higher ORR compared with chemotherapy alone, but these results did not translate into a PFS or OS advantage, suggesting that prior administration of PD-1 inhibitors may result in a synergistic antitumor effect with subsequent chemotherapy, but that such an effect is transient.
Journal ArticleDOI
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience
Toshio Shimizu,Taroh Satoh,Kenji Tamura,Tomohiro Ozaki,Isamu Okamoto,Masahiro Fukuoka,Kazuhiko Nakagawa +6 more
TL;DR: Both FOLFOX regimens have good efficacy in refractory or advanced colorectal cancer in a Japanese population, with an acceptable overall toxicity profile.
Journal ArticleDOI
Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer
Kenji Tamura,Isamu Okamoto,Tomohiro Ozaki,Tatsuhiko Kashii,Koji Takeda,Masashi Kobayashi,Kaoru Matsui,Takashi Shibata,Takayasu Kurata,Kazuhiko Nakagawa,Masahiro Fukuoka +10 more
TL;DR: This is the first report to show promising activity of this combination in phase II, including survival data and manageable toxicity, especially in outpatients receiving treatment for advanced NSCLC.